- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Takeda Targets Most Promising Markets
05 October
Takeda is to set up four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg as part of its strategic global expansion effort. Mexico represents the world's 12th largest pharma market and accounts for around 25% of the pharmaceutical sales in Latin America. Turkey comes in at number 13 worldwide (sixth in Europe) and has the fastest forecasted growth rate in Europe over the next five years. Norway, Sweden, Denmark, Belgium and Luxembourg combined account for 5% of the European pharmaceutical market. The new subsidiaries will strengthen Takeda's expansion efforts for products such as Actos (pioglitazone), which the company bought back in October last year.
Alan MacKenzie, Takeda's EVP. International Operations, commented: "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."
Click here for Takeda Europe CEO Erich Brunn's take on the global expansion strategy.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
